# SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC

Source: https://onco.cc/trials/nct07198165/  
OnCo record `nct07198165` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Ruijin Hospital, now recruiting.

## Summary

SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC is a phase 2, randomised interventional study registered as NCT07198165 by Ruijin Hospital, with a registry enrolment figure of 104 participants, started 2025-09-05 and due to reach its primary completion in 2030-12-31. Interventions recorded: PD-1 inhibitor based immunotherapy. Conditions listed: Rectal Cancer; Rectal Adenocarcinoma; Rectal Cancer, Radiotherapy; Rectal Cancer Patients; Immunotherapy; Total Neoadjuvant Therapy; Total Neoadjuvant Treatment; Targeted Therapy; Chemoradiotherapy. Primary outcome: Complete Response rate. Colorectal eligibility wording from the registry: "* Histopathologically confirmed rectal adenocarcinoma with no prior antitumor therapy". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07198165
- Phase: 2
- Setting: Short-Course Radiotherapy Combined With CAPOX and Bevacizumab, With or Without PD-1 Inhibitors, as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
- Sponsor: Ruijin Hospital
- Enrolled: 104

## Sources

- ClinicalTrials.gov NCT07198165: https://clinicaltrials.gov/study/NCT07198165

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07198165.json